Added to YB: 2025-02-04
Pitch date: 2025-02-04
MDP.TO [bullish]
Medexus Pharmaceuticals Inc.
+27.44%
current return
Author Info
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 113.3M
Pitch Price
CAD 3.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.29
P/E
-48.30
EV/Sales
1.30
Sector
Pharmaceuticals
Category
growth
A big catalyst has the potential to double revenue and triple EBITDA...
MDP.TO: Specialty pharma at 5x EV/EBITDA (EV $94M). Legacy drugs (IXINITY, Rupall, Gleolan) declining, but newly FDA-approved treosulfan could double revenue and triple EBITDA over 5yrs, targeting $100M+ sales vs busulfan. FY26 EBITDA dips on ramp costs; FY28E ~$34M EBITDA. Net debt $13M + $15M milestone due. Lubracis nail-fungus drug optional catalyst. Speculative, 4-5% position.
Read full article (7 min)